Navigation Links
Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
Date:3/7/2011

LAKE FOREST, Ill., March 7, 2011 /PRNewswire/ -- The board of directors of Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced the election of F. Michael (Mike) Ball as the company's new chief executive officer (CEO) and a member of the board, effective March 28, 2011. Mr. Ball, 55, currently President, Allergan, Inc., succeeds the company's founding CEO, Christopher B. Begley, who will assume the role of executive chairman.

(Photo:  http://photos.prnewswire.com/prnh/20110307/CG60745)

"From the outset of our CEO search, the board and I were determined to identify a candidate who would extend Hospira's growth trajectory, expand our global reach, and inspire our employees as we continue our patient-focused journey to sustainable top-tier financial performance," said Mr. Begley. "With his proven track record of growing complex global businesses, demonstrated success in leading diversified healthcare portfolios and strong commitment to creating value for all company stakeholders, we found the perfect fit with Mike Ball. We are thrilled to welcome Mike to the Hospira family, and I look forward to partnering with him and our board to continue to advance our great company – a company that is stronger and better positioned for success now than at any point in our rich history."

Mr. Ball joins Hospira following a distinguished 16-year career with Allergan, a multi-specialty healthcare company with a presence in more than 100 countries and a broad portfolio of pharmaceuticals, biologics and medical devices. During his tenure at Allergan, Mr. Ball was responsible for accelerating growth in international markets and leading the strategy and execution of global commercial activities for a diverse slate of businesses, including specialty pharmaceuticals, over-the-counter products and surgical devices.

Recognized for his intense customer focus and exceptional results, Mr. Ball helped drive top-tier financial performance over a 10-year period and earn the No. 1 or No. 2 market share position in most of the company's marketed therapeutic categories.

Said Mr. Ball, "I am deeply honored and excited to join Hospira's 14,000 employees in advancing our shared passion to increase patient and caregiver safety and productivity, reduce the high costs of healthcare, and provide the highest quality products that address critical unmet needs around the globe. With our strong financial position, market leadership and talented workforce, Hospira is uniquely positioned to capitalize on our exceptional growth potential while we create value for our employees, customers, shareholders and global communities."

Commenting on Mr. Ball's appointment, Irving W. Bailey, II, Hospira's lead independent director, said, "Mike brings to Hospira more than 25 years of global healthcare experience, an outstanding record of results-oriented performance and clear alignment with our strategy and culture. The board is confident that he is the right person to lead Hospira's continued growth and success." Added Mr. Bailey, "Working together, Chris and Mike will ensure a seamless transition for our employees, customers and shareholders, and we are deeply grateful for Chris' continued, active leadership in the role of executive chairman."

As executive chairman, Mr. Begley will focus on ensuring continuity of leadership, providing strategic counsel to Mr. Ball and managing an orderly transition of the CEO responsibilities.

Mr. Begley assumes the executive chairman role after launching Hospira as the company's founding CEO following its 2004 spin-off from Abbott Laboratories. During his tenure, Hospira doubled its market capitalization, geographic footprint and revenue outside the United States; improved adjusted gross margins by more than 1,000 basis points; and generated more than $3 billion in cash flow from operations.

For more information on key company facts and accomplishments, visit:


About F. Michael Ball

Prior to his appointment as Hospira CEO, and since 2006, Mr. Ball served as the President of Allergan. He joined the company in 1995 and held a number of leadership roles including Executive Vice President and President, Pharmaceuticals; President, North America Region and President, Global Eyecare.

Before Allergan, Mr. Ball served as Senior Vice President for Syntex Laboratories USA and President, Syntex Canada, where his responsibilities spanned marketing, sales, regulatory and clinical functions, as well as the creation of an authorized generics business. He started his healthcare career at Eli Lilly and Company.

Born in Canada, Mr. Ball earned both his bachelor's degree in life sciences and his master of business administration degree in marketing at Queen's University, Ontario, Canada. He completed an executive management program at Stanford University and has served on the board of STEC, Inc. since 2000.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 -

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira MedNet™ Portal Safety Software Benchmarking System Debuts at HIMSS
2. Hospira to Present at Upcoming Investor Conferences
3. Hospira Announces FDA Approval of Topotecan Injection
4. Hospira Reports Fourth-Quarter and Full-Year 2010 Results
5. Hospira to Host Conference Call for Fourth-Quarter 2010 Results and 2011 Projections
6. Hospira Launches Piperacillin and Tazobactam for Injection in the United States
7. Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment
8. Hospira to Host Conference Call for Third-Quarter 2010 Results
9. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
10. Hospira Japan Receives Approval for New Indication for Precedex IV™ 200ug
11. Hospira Announces CEO Succession Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):